Array
(
[id] => 447
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/447.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] => https://www.jcvaonline.com/article/S1053-0770(19)30296-4/fulltext
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => the Network for the Advancement of Patient Blood M
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend against the use of desmopressin for bleeding management in children undergoing cardiac surgery. (1B)
[laiyuan] => 推荐对接受心脏手术的儿童不使用去氨加压素治疗出血。（证据等级：中；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
推荐对接受心脏手术的儿童不使用去氨加压素治疗出血。（证据等级：中；推荐强度：强推荐）
We recommend against the use of desmopressin for bleeding management in children undergoing cardiac surgery. (1B)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：the Network for the Advancement of Patient Blood M
Array
(
[id] => 448
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/448.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => the Network for the Advancement of Patient Blood M
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend against the administration of rFVIIa to treat acquired coagulopathy in neonate and children undergoing cardiac surgery. (1C)
[laiyuan] => 推荐不要使用rFVIIa治疗接受心脏手术的新生儿和儿童的获得性凝血病。（证据等级：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
推荐不要使用rFVIIa治疗接受心脏手术的新生儿和儿童的获得性凝血病。（证据等级：低；推荐强度：强推荐）
We recommend against the administration of rFVIIa to treat acquired coagulopathy in neonate and children undergoing cardiac surgery. (1C)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：the Network for the Advancement of Patient Blood M
Array
(
[id] => 449
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/449.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => the Network for the Advancement of Patient Blood M
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend against the use of PCC in pediatric cardiac surgery unless it is part of a clinical trial. (1C)
[laiyuan] => 建议不要在小儿心脏手术中使用凝血酶原复合物（PCC），除非它是临床试验的一部分。（证据等级：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
建议不要在小儿心脏手术中使用凝血酶原复合物（PCC），除非它是临床试验的一部分。（证据等级：低；推荐强度：强推荐）
We recommend against the use of PCC in pediatric cardiac surgery unless it is part of a clinical trial. (1C)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：the Network for the Advancement of Patient Blood M
Array
(
[id] => 450
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/450.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => the Network for the Advancement of Patient Blood M
[pdf] =>
[tjyjyw] =>
[lyyw] => We suggest fresh frozen plasma should ONLY be considered for treating hypofibrinogenemia in bleeding neonates and children when cryoprecipitate or fibrinogen concentrate are not available. (2C)
[laiyuan] => 建议只有在无法获得低温沉淀物或浓缩纤维蛋白原的情况下，才可考虑使用新鲜冰冻血浆治疗出血新生儿和儿童的低纤维蛋白原血症。（证据等级：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
建议只有在无法获得低温沉淀物或浓缩纤维蛋白原的情况下，才可考虑使用新鲜冰冻血浆治疗出血新生儿和儿童的低纤维蛋白原血症。（证据等级：低；推荐强度：弱推荐）
We suggest fresh frozen plasma should ONLY be considered for treating hypofibrinogenemia in bleeding neonates and children when cryoprecipitate or fibrinogen concentrate are not available. (2C)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：the Network for the Advancement of Patient Blood M
Array
(
[id] => 451
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/451.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => 加拿大、奥地利、英国、比利时
[pdf] =>
[tjyjyw] =>
[lyyw] => For newborns and children diagnosed with hypofibrinogenemia, we recommend treatment with cryoprecipitated or concentrated fibrinogen. (2C)
[laiyuan] => 对于诊断为低纤维蛋白原血症的新生儿和儿童，我们推荐使用低温沉淀或浓缩纤维蛋白原进行治疗。（证据等级：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于诊断为低纤维蛋白原血症的新生儿和儿童，我们推荐使用低温沉淀或浓缩纤维蛋白原进行治疗。（证据等级：低；推荐强度：弱推荐）
For newborns and children diagnosed with hypofibrinogenemia, we recommend treatment with cryoprecipitated or concentrated fibrinogen. (2C)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：加拿大、奥地利、英国、比利时
Array
(
[id] => 452
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/452.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => the Network for the Advancement of Patient Blood M
[pdf] =>
[tjyjyw] =>
[lyyw] => In bleeding neonates and children, we recommend hypofibrinogenemia diagnosed either by Clauss method (< 1.5 g/L) or viscoelastic tests (based on institution-specific algorithm) should be treated. (1C)
[laiyuan] => 对于出血的新生儿和儿童，建议应通过克劳斯法（<1.5g/L）或粘弹性测试（基于特定机构的算法）诊断出低纤维蛋白原血症。。（证据等级：低；推荐强度：强推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
对于出血的新生儿和儿童，建议应通过克劳斯法（<1.5g/L）或粘弹性测试（基于特定机构的算法）诊断出低纤维蛋白原血症。。（证据等级：低；推荐强度：强推荐）
In bleeding neonates and children, we recommend hypofibrinogenemia diagnosed either by Clauss method (< 1.5 g/L) or viscoelastic tests (based on institution-specific algorithm) should be treated. (1C)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：the Network for the Advancement of Patient Blood M
Array
(
[id] => 453
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/453.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => the Network for the Advancement of Patient Blood M
[pdf] =>
[tjyjyw] =>
[lyyw] => In the presence of excessive bleeding post CPB despite adequate heparin reversal, we suggest platelet transfusion. (2C)
[laiyuan] => 如果在充分逆转肝素后仍出现体外循环后出血过多的情况，建议输注血小板。（证据等级：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
如果在充分逆转肝素后仍出现体外循环后出血过多的情况，建议输注血小板。（证据等级：低；推荐强度：弱推荐）
In the presence of excessive bleeding post CPB despite adequate heparin reversal, we suggest platelet transfusion. (2C)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：the Network for the Advancement of Patient Blood M
Array
(
[id] => 454
[catid] => 243
[title] => Patient Blood Management for Neonates and Children undergoing Cardiac Surgery: 2019 NATA guidelines
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/454.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:39
[updatetime] => 2024-01-11 15:12:39
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => GRADE
[zjfj] =>
[tjqd] =>
[nianfen] => 2019
[guojia] => the Network for the Advancement of Patient Blood M
[pdf] =>
[tjyjyw] =>
[lyyw] => We recommend a postoperative hemoglobin threshold for transfusion in stable cyanotic cardiac children with clinical signs suggestive of symptomatic anemia as of 90 g/L. (2C)
[laiyuan] => 推荐有临床症状提示症状性贫血的稳定型紫绀型心脏病患儿术后输血的血红蛋白阈值为90g/L。（证据等级：低；推荐强度：弱推荐）
[znzldj] => B
[_inputtime] => 1704957159
[_updatetime] => 1704957159
[_nrjc] =>
[_nrsh] =>
)
推荐意见
推荐有临床症状提示症状性贫血的稳定型紫绀型心脏病患儿术后输血的血红蛋白阈值为90g/L。（证据等级：低；推荐强度：弱推荐）
We recommend a postoperative hemoglobin threshold for transfusion in stable cyanotic cardiac children with clinical signs suggestive of symptomatic anemia as of 90 g/L. (2C)
证据评价方法：GRADE
指南质量等级：B
年份：2019
国家：the Network for the Advancement of Patient Blood M
Array
(
[id] => 400
[catid] => 138
[title] => European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/400.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:38
[updatetime] => 2024-01-11 15:12:38
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => Infectious Diseases Society of America–United Stat
[zjfj] =>
[tjqd] =>
[nianfen] => 2021
[guojia] => European Society of Gynaecological Oncology
[pdf] =>
[tjyjyw] =>
[lyyw] => There is no well- defined threshold for blood transfusion in advanced ovarian cancer surgery. Since many patients need chemotherapy, more liberal transfusion thresholds may be used. (II, B)
[laiyuan] => 晚期卵巢癌手术中输血没有明确的阈值。由于许多患者需要化疗，可以使用更自由的输血阈值（证据等级：II；推荐强度：B）。
[znzldj] => B
[_inputtime] => 1704957158
[_updatetime] => 1704957158
[_nrjc] =>
[_nrsh] =>
)
推荐意见
晚期卵巢癌手术中输血没有明确的阈值。由于许多患者需要化疗，可以使用更自由的输血阈值（证据等级：II；推荐强度：B）。
There is no well- defined threshold for blood transfusion in advanced ovarian cancer surgery. Since many patients need chemotherapy, more liberal transfusion thresholds may be used. (II, B)
证据评价方法：Infectious Diseases Society of America–United Stat
指南质量等级：B
年份：2021
国家：European Society of Gynaecological Oncology
Array
(
[id] => 401
[catid] => 138
[title] => European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery
[thumb] =>
[keywords] =>
[description] =>
[hits] =>
[uid] => 1
[author] => 系统管理员
[status] => 9
[url] => /show/401.html
[link_id] => 0
[tableid] => 0
[inputip] => 14.105.95.222
[inputtime] => 2024-01-11 15:12:38
[updatetime] => 2024-01-11 15:12:38
[displayorder] => 0
[nrjc] => Array
(
)
[nrsh] => Array
(
)
[xzl] => 0
[dzl] => 0
[wailian] =>
[demo_url] =>
[zjpjff] => Infectious Diseases Society of America–United Stat
[zjfj] =>
[tjqd] =>
[nianfen] => 2021
[guojia] => European Society of Gynaecological Oncology
[pdf] =>
[tjyjyw] =>
[lyyw] => Tranexamic acid should be considered peri- operatively reduce blood loss. (I, B)
[laiyuan] => 围手术期应考虑使用氨甲环酸以减少失血。（证据等级：I；推荐强度：B）
[znzldj] => B
[_inputtime] => 1704957158
[_updatetime] => 1704957158
[_nrjc] =>
[_nrsh] =>
)
推荐意见
围手术期应考虑使用氨甲环酸以减少失血。（证据等级：I；推荐强度：B）
Tranexamic acid should be considered peri- operatively reduce blood loss. (I, B)
证据评价方法：Infectious Diseases Society of America–United Stat
指南质量等级：B
年份：2021
国家：European Society of Gynaecological Oncology
